Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants.

Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants. CMAJ. 2019 Aug 12;191(32):E886-E893 Authors: Walker M, Jacobson M, Sobel M PMID: 31405835 [PubMed - in process]
Source: cmaj - Category: General Medicine Authors: Tags: CMAJ Source Type: research

Related Links:

AbstractFirst-line chemotherapy for many solid tumors is limited by toxicity. There is a growing interest in maintenance therapy as a strategy for prolonging the benefits of first-line therapy while minimizing toxicity. Maintenance therapy can comprise either continuation of an agent given as part of the first-line regimen (continuation maintenance) or treatment with a new agent (switch maintenance). Maintenance therapy is already established in several solid tumors, including lung, breast, gastric, colorectal, and ovarian cancer. Immune checkpoint inhibitor treatment has been shown to prolong duration of response and over...
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: Nurses are at a higher risk of developing endometriosis. However, the link between endometriosis and subsequent cancers is weak.
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
(Natural News) Scutellaria baicalensis, also known as Chinese skullcap, is a flowering plant used in traditional Chinese medicine. Its roots have been used since ancient times to treat various conditions, such as inflammation, hypertension, psoriasis, and respiratory infections. S. baicalensis contains many active components, the most widely studied of which are the flavonoids baicalin and baicalein. Baicalin has been shown to...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
ConclusionsCollectively, our findings suggest that ROR1-IgG may be a novel therapeutic agent for patients with ROR1-positive ovarian cancer.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Authors: Tan WX, Xu TM, Zhou ZL, Lv XJ, Liu J, Zhang WJ, Cui MH Abstract Cisplatin is a common chemotherapeutic agent against ovarian cancer; however, drug resistance is a major limiting factor for its use in clinical treatment. The underlying mechanisms of cisplatin resistance in ovarian cancer have not yet been fully elucidated. Thus, this study aimed to elucidate some of the mechanisms responsible for resistance to cisplatin in ovarian cancer. The results demonstrated that the cisplatin‑resistant human ovarian cancer cell lines, SKOV3/DDP and A2780/DDP, exhibited higher autophagy levels than the control ovaria...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   FIGO Grade 1 Endometrial Endometrioid Adenocarcinom a;   FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma;   FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Gra...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractThe identification of germline pathogenic/likely pathogenic (P/LP) variants in cancer predisposition genes can guide treatment and management decisions for the individual being tested and potentially at-risk relatives. Prior studies have raised concerns of racial/ethnic disparities in the detection rates of P/LP variants and variants of uncertain significance (VUSs). In 2018, Color Genomics ™, a commercial laboratory, made de-identified, aggregate genetic and clinical information from 50,000 individuals who completed testing for 30 cancer predisposition genes publicly available. It is the largest publicly ava...
Source: Familial Cancer - Category: Cancer & Oncology Source Type: research
Ovarian cancer and Immune checkpointsFor more information go tohttps://www.cancer.gov/grants-training/training/resources-trainees/courses-fellowships/translational-research-clinical oncologyAir date: 10/7/2019 4:00:00 PM
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video
Condition:   BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer Intervention:   Drug: Olaparib tablets Sponsor:   National Cancer Institute, Naples Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Premenopausal women who undergo surgical removal of ovaries and fallopian tubes to lower cancer risk are found to have higher rates of bone loss, according to a study publish inJAMA Network Open.Rheumatology Advisor
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
More News: Cancer | Cancer & Oncology | General Medicine | Ovarian Cancer | Ovaries | Women